Christopher Benecchi is Chief Operating Officer of Sage Therapeutics, Inc.. Currently has a direct ownership of 24,737 shares of SAGE, which is worth approximately $130,611. The most recent transaction as insider was on Nov 01, 2024, when has been sold 6,250 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.7K
33.81% 3M change
370.29% 12M change
Total Value Held $130,611

Christopher Benecchi Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 01 2024
BUY
Grant, award, or other acquisition
-
6,250 Added 20.17%
24,737 Common Stock
Aug 05 2024
SELL
Payment of exercise price or tax liability
$42,604 $8.96 p/Share
4,755 Reduced 20.46%
18,487 Common Stock
Aug 05 2024
BUY
Grant, award, or other acquisition
-
16,200 Added 41.07%
23,242 Common Stock
Feb 13 2024
BUY
Grant, award, or other acquisition
-
13,500 Added 41.0%
19,430 Common Stock
Feb 03 2023
SELL
Payment of exercise price or tax liability
$93,575 $44.16 p/Share
2,119 Reduced 28.72%
5,260 Common Stock
Feb 03 2023
BUY
Grant, award, or other acquisition
-
6,750 Added 47.77%
7,379 Common Stock
CB

Christopher Benecchi

Chief Operating Officer
Cambridge, MA

Track Institutional and Insider Activities on SAGE

Follow Sage Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SAGE shares.

Notify only if

Insider Trading

Get notified when an Sage Therapeutics, Inc. insider buys or sells SAGE shares.

Notify only if

News

Receive news related to Sage Therapeutics, Inc.

Track Activities on SAGE